Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Accesswire October 1, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Newsfile October 1, 2024

Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire October 1, 2024

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire October 1, 2024

Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 30, 2024

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - VERV

Newsfile September 30, 2024

Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 30, 2024

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 30, 2024

The Schall Law Firm Urges Investors To Take Part In A Securities Fraud Case Against Verve Therapeutics, Inc.

Accesswire September 30, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

Accesswire September 30, 2024

VERV Shareholders Have Opportunity to Lead Verve Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Accesswire September 30, 2024

Investors in Verve Therapeutics, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV

PR Newswire September 30, 2024

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire September 29, 2024

Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Help The Schall Law Firm

Accesswire September 29, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

Accesswire September 29, 2024

Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 29, 2024

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - VERV

Newsfile September 29, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Accesswire September 29, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Verve Therapeutics, Inc.(VERV) Shareholders

Accesswire September 28, 2024

The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.

Accesswire September 28, 2024